Dihexa raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-06. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The foursubstrates of this enzyme are 3-hydroxybenzoic acid, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. Its products are protocatechuic acid, oxidised NADP+, and water. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 3-hydroxybenzoate,NADPH:oxygen oxidoreductase (4-hydroxylating). It is also called 3-hydroxybenzoate 4-hydroxylase. It participates in benzoate degradation via hydroxylation and uses flavin adenine dinucleotide as a cofactor.
Angelopoulos was awarded honorary doctorates by the Université libre de Bruxelles, Belgium in 1995, by Paris West University Nanterre La Défense, France, by the University of Essex, UK in July 2001, by the University of Western Macedonia, Greece in December 2008, and by the University of the Aegean, Greece in December 2009.
== Production == The film was first announced in October 2014 as a live action adaptation of Dark Horse Comics' Polar, developed by Dark Horse Entertainment and Constantin Film. A spec script for the film by Jayson Rothwell was purchased. In October 2017, Mads Mikkelsen signed on to star in the film. In February 2018, Vanessa Hudgens, Katheryn Winnick and Matt Lucas joined the cast with Netflix onboard to distribute the film. Filming began early February 2018 in Orono, Ontario, Canada, and continued around February 23 in Toronto, Ontario, with Swedish director Jonas Åkerlund at the helm. Among various filming locations used was the residence of musician Deadmau5, for the opening scene. In September 2018, Deadmau5 announced that he was in the process of producing the film's original score. Netflix started streaming the film on January 25, 2019, with Deadmau5 releasing the soundtrack on the same day.
As a bacteriologist, Miller was enthusiastic about the antibacterial project; he encouraged Florey to apply for a grant from the Rockefeller Foundation, and recommended to his headquarters that the request for financial support be given serious consideration. "The work proposed", Florey wrote in his application letter, "in addition to its theoretical importance, may have practical value for therapeutic purposes." Florey's application was approved, with the Rockefeller Foundation allocating US$5,000 (£1,250) per annum for five years. Florey's team already had a sample of penicillin mould; Dreyer had been given a sample of the mould in 1930 for his work on bacteriophages. He had lost interest in penicillin when he discovered that it was not a bacteriophage, but Campbell-Renton had continued to cultivate it. The team developed techniques for growing the mould on a surface of liquid Czapek-Dox medium. Most laboratory containers did not provide a large, flat area, so glass bottles laid on their sides were used. Later, specially-made containers were fabricated. As the laboratory gradually became a penicillin factory, Florey hired six women to perform the cultivation and extraction work. It had to be carried out under sterile conditions; Abraham and Chain discovered that some airborne bacteria produced penicillinase, an enzyme that destroys penicillin. Heatley and Chain tackled the problem of how penicillin could be extracted from the mould. The liquid was filtered through parachute silk to remove the mycelium, spores and other solid debris.
Sources: en.wikipedia.org
Complete list of OTC drugs "Over-the-Counter Medicines Guide" Archived 9 March 2021 at the Wayback Machine, Tool Box at ConsumerMedSafety.org Over-the-counter (OTC) medicines at FamilyDoctor.org, maintained by the American Academy of Family Physicians. Contains extensive information on over-the-counter drugs and their responsible use, including specific guidance on several drug classes in question-and-answer format and information on common drug interactions. UK Medicines and Healthcare Products Regulatory Agency list of substances on general sales list Archived 7 March 2014 at the Wayback Machine National Institute on Drug Abuse: "NIDA for Teens: Cough and Cold Medicine (DXM and Codeine Syrup)"
Niobium-95, with a half-life of 35 days, is initially present as a fission product. The only stable isotope of niobium has mass number 93, and fission products of mass 93 first decay to long-lived zirconium-93 (half-life 1.53 Ma). Niobium-95 will decay to molybdenum-95 which is stable.
On 2 May, a report accompanied by an open letter concludes that Alphabet Inc, against its voluntary promises, still runs climate misinformation ads. Statements by Elon Musk in 2022 suggest YouTube may also show ethically disputed advertising other than science-related misinformation such as extensively showing "scam ads". 25 May 5,000 marine species new to science are discovered in the Clipperton fracture zone, a proposed deep sea mining hotspot in the Pacific Ocean. Explainable deep learning is used to develop an experimental antibiotic called abaucin, which is shown to be effective against A. baumannii. Evidence for the existence of a second Kuiper Belt is presented by NASA scientists, which the New Horizons spacecraft could potentially visit during the late 2020s or early 2030s. A study reports observational evidence for problematic fast slowdown of the Antarctic bottom water current. Neuroengineers demonstrate induction of a torpor-like state in mice via ultrasound stimulation. 29 May A new record high efficiency of 19.3% for organic solar cells is reported. MBR Explorer is announced by the United Arab Emirates Space Agency, an uncrewed mission to explore seven asteroids, which includes an attempted surface landing on 269 Justitia in 2034. Scientists provide details of H5N1 bird flu's fast viral evolution of clade 2.3.4.4b including reassortment after "explosive geographic expansion in 2021 among wild birds", with relevance to measures such as existing candidate vaccines. 31 May The first X-ray of a single atom is reported.
Sources: en.wikipedia.org
In 1882, he was appointed professor of chemistry at the University of Erlangen and in 1885 at the University of Würzburg. In 1892, he succeeded von Hofmann as professor of chemistry at the Friedrich Wilhelm University of Berlin.
Common barbiturate side effects include nausea, hypotension, headache, drowsiness, and skin rash. More serious side effects can include confusion, slow breathing, hallucination, fainting, and coma. Rare side effects may include agranulocytosis, liver injury, megaloblastic anemia, or Stevens-Johnson Syndrome.
== Toxicity == Azacitidine causes anemia (low red blood cell counts), neutropenia (low white blood cell counts), and thrombocytopenia (low platelet counts), and patients should have frequent monitoring of their complete blood counts, at least prior to each dosing cycle. The dose may have to be adjusted based on nadir counts and hematologic response. It can also be hepatotoxic in patients with severe liver impairment, and patients with extensive liver tumors due to metastatic disease have developed progressive hepatic coma and death during azacitidine treatment, especially when their albumin levels are less than 30 g/L. It is contraindicated in patients with advanced malignant hepatic tumors. Kidney toxicity, ranging from elevated serum creatinine to kidney failure and death, have been reported in patients treated with intravenous azacitidine in combination with other chemotherapeutic agents for conditions other than myelodysplastic syndrome. Renal tubular acidosis developed in five patients with chronic myelogenous leukemia (an unapproved use) treated with azacitidine and etoposide, and patients with renal impairment may be at increased risk for renal toxicity. Azacitidine and its metabolites are primarily excreted by the kidneys, so patients with chronic kidney disease should be closely monitored for other side effects, since their levels of azacitidine may progressively increase. Based on animal studies and its mechanism of action, azacitidine can cause severe fetal damage.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.